Comparative Pharmacology
Head-to-head clinical analysis: MECLOMEN versus TAB PROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLOMEN versus TAB PROFEN.
MECLOMEN vs TAB-PROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclomen (meclofenamate) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This results in anti-inflammatory, analgesic, and antipyretic effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor; reduces prostaglandin synthesis.
50-100 mg orally every 6-8 hours; maximum 400 mg/day.
400-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 0.8–1.1 hours for meclofenamic acid; 2–4 hours for metabolites. Short half-life requires frequent dosing (e.g., every 6–8 hours) for sustained effect.
The terminal elimination half-life is 2-4 hours in adults with normal renal function. In elderly patients or those with renal impairment, half-life may be prolonged up to 8-12 hours, requiring dose adjustment.
Renal (approximately 70% as metabolites, <5% unchanged); fecal/biliary (approximately 30% as metabolites).
Renal excretion of unchanged drug accounts for approximately 70-90% of the administered dose, with the remainder eliminated as glucuronide conjugates in urine. Biliary/fecal elimination is minimal (<5%).
Category C
Category C
NSAID
NSAID